Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395310619> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2395310619 endingPage "2" @default.
- W2395310619 startingPage "70" @default.
- W2395310619 abstract "Thirty-five patients with stage III B non-small cell lung cancer were treated with the combination of cisplatin (CDDP) 30 mg/M2/day and etoposide (VP16-213) 75 mg/M2/day administered as a 72-hour infusion. Twenty evaluable patients (67%) received subsequent thoracic radiation as definitive regional therapy following a clinical response or stable disease status. Complete plus partial responses to chemotherapy were observed in 15 patients (5CR and 10PR or 44%). Of the 20 patients who received radiation, six responded with five transitioning from stable disease to partial (2) or complete (3) responses. The overall response rate to the combined sequential chemotherapy plus radiation was therefore 20/35 or 59% with eight complete responders. Histopathology influenced the response rate to chemotherapy (53% versus 30% for epidermoid versus adenocarcinomas, respectively), but following radiation, the response rates were similar for the two pathologic subtypes (73% versus 71%). Median overall survival was 363 days with 20% of patients alive at 13 to 45 months. The response rate for CDDP plus VP16-213 chemotherapy administered as a 72-hour infusion was superior for stage III B non-small cell lung cancer compared with stage IV disease as previously reported by the Mid Atlantic Oncology Program (44% versus 25%). This difference between stage III B and stage IV was also reflected in median survival (363 days versus 190 days). The sequential addition of radiation therapy to this chemotherapy regimen is feasible in stage III B disease with a small proportion of patients demonstrating long-term survival." @default.
- W2395310619 created "2016-06-24" @default.
- W2395310619 creator A5017313229 @default.
- W2395310619 creator A5017790665 @default.
- W2395310619 creator A5057509756 @default.
- W2395310619 creator A5083054835 @default.
- W2395310619 creator A5089008430 @default.
- W2395310619 date "1995-01-01" @default.
- W2395310619 modified "2023-09-27" @default.
- W2395310619 title "Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188." @default.
- W2395310619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8521238" @default.
- W2395310619 hasPublicationYear "1995" @default.
- W2395310619 type Work @default.
- W2395310619 sameAs 2395310619 @default.
- W2395310619 citedByCount "0" @default.
- W2395310619 crossrefType "journal-article" @default.
- W2395310619 hasAuthorship W2395310619A5017313229 @default.
- W2395310619 hasAuthorship W2395310619A5017790665 @default.
- W2395310619 hasAuthorship W2395310619A5057509756 @default.
- W2395310619 hasAuthorship W2395310619A5083054835 @default.
- W2395310619 hasAuthorship W2395310619A5089008430 @default.
- W2395310619 hasConcept C121608353 @default.
- W2395310619 hasConcept C126322002 @default.
- W2395310619 hasConcept C141071460 @default.
- W2395310619 hasConcept C146357865 @default.
- W2395310619 hasConcept C151730666 @default.
- W2395310619 hasConcept C2776256026 @default.
- W2395310619 hasConcept C2776283816 @default.
- W2395310619 hasConcept C2776694085 @default.
- W2395310619 hasConcept C2778119113 @default.
- W2395310619 hasConcept C2778239845 @default.
- W2395310619 hasConcept C2778336483 @default.
- W2395310619 hasConcept C2778822529 @default.
- W2395310619 hasConcept C2781413609 @default.
- W2395310619 hasConcept C509974204 @default.
- W2395310619 hasConcept C71924100 @default.
- W2395310619 hasConcept C86803240 @default.
- W2395310619 hasConcept C90924648 @default.
- W2395310619 hasConceptScore W2395310619C121608353 @default.
- W2395310619 hasConceptScore W2395310619C126322002 @default.
- W2395310619 hasConceptScore W2395310619C141071460 @default.
- W2395310619 hasConceptScore W2395310619C146357865 @default.
- W2395310619 hasConceptScore W2395310619C151730666 @default.
- W2395310619 hasConceptScore W2395310619C2776256026 @default.
- W2395310619 hasConceptScore W2395310619C2776283816 @default.
- W2395310619 hasConceptScore W2395310619C2776694085 @default.
- W2395310619 hasConceptScore W2395310619C2778119113 @default.
- W2395310619 hasConceptScore W2395310619C2778239845 @default.
- W2395310619 hasConceptScore W2395310619C2778336483 @default.
- W2395310619 hasConceptScore W2395310619C2778822529 @default.
- W2395310619 hasConceptScore W2395310619C2781413609 @default.
- W2395310619 hasConceptScore W2395310619C509974204 @default.
- W2395310619 hasConceptScore W2395310619C71924100 @default.
- W2395310619 hasConceptScore W2395310619C86803240 @default.
- W2395310619 hasConceptScore W2395310619C90924648 @default.
- W2395310619 hasIssue "2" @default.
- W2395310619 hasLocation W23953106191 @default.
- W2395310619 hasOpenAccess W2395310619 @default.
- W2395310619 hasPrimaryLocation W23953106191 @default.
- W2395310619 hasRelatedWork W2086955530 @default.
- W2395310619 hasRelatedWork W2152552894 @default.
- W2395310619 hasRelatedWork W2157562330 @default.
- W2395310619 hasRelatedWork W2260720093 @default.
- W2395310619 hasRelatedWork W2263955356 @default.
- W2395310619 hasRelatedWork W2352319395 @default.
- W2395310619 hasRelatedWork W2389384568 @default.
- W2395310619 hasRelatedWork W2416304715 @default.
- W2395310619 hasRelatedWork W2417697013 @default.
- W2395310619 hasRelatedWork W2767052226 @default.
- W2395310619 hasVolume "5" @default.
- W2395310619 isParatext "false" @default.
- W2395310619 isRetracted "false" @default.
- W2395310619 magId "2395310619" @default.
- W2395310619 workType "article" @default.